Malignant melanoma—The cradle of anti-neoplastic immunotherapy

Kristian M. Koller; Wenge Wang; Todd D. Schell; Eugene M. Cozza; Kathleen M. Kokolus; Rogerio I. Neves; Heath B. Mackley; Colette Pameijer; Anna Leung; Bryan Anderson; Carol A. Mallon; Gavin Robertson; Joseph J. Drabick

doi:10.1016/j.critrevonc.2016.04.010

Malignant melanoma—The cradle of anti-neoplastic immunotherapy

Kristian M. Koller, Wenge Wang, Todd D. Schell, Eugene M. Cozza, Kathleen M. Kokolus, Rogerio I. Neves, Heath B. Mackley, Colette Pameijer, Anna Leung, Bryan Anderson, Carol A. Mallon, Gavin Robertson, Joseph J. Drabick

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

Original language	English (US)
Pages (from-to)	25-54
Number of pages	30
Journal	Critical Reviews in Oncology/Hematology
Volume	106
DOIs	https://doi.org/10.1016/j.critrevonc.2016.04.010
State	Published - Oct 1 2016

All Science Journal Classification (ASJC) codes

Hematology
Oncology

Access to Document

10.1016/j.critrevonc.2016.04.010

Cite this

@article{529b4d3d9e334da2b11cf0cb791149d2,

title = "Malignant melanoma—The cradle of anti-neoplastic immunotherapy",

abstract = "One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.",

author = "Koller, {Kristian M.} and Wenge Wang and Schell, {Todd D.} and Cozza, {Eugene M.} and Kokolus, {Kathleen M.} and Neves, {Rogerio I.} and Mackley, {Heath B.} and Colette Pameijer and Anna Leung and Bryan Anderson and Mallon, {Carol A.} and Gavin Robertson and Drabick, {Joseph J.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ireland Ltd",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.critrevonc.2016.04.010",

language = "English (US)",

volume = "106",

pages = "25--54",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Malignant melanoma—The cradle of anti-neoplastic immunotherapy

AU - Koller, Kristian M.

AU - Wang, Wenge

AU - Schell, Todd D.

AU - Cozza, Eugene M.

AU - Kokolus, Kathleen M.

AU - Neves, Rogerio I.

AU - Mackley, Heath B.

AU - Pameijer, Colette

AU - Leung, Anna

AU - Anderson, Bryan

AU - Mallon, Carol A.

AU - Robertson, Gavin

AU - Drabick, Joseph J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

AB - One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84994834554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994834554&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.04.010

DO - 10.1016/j.critrevonc.2016.04.010

M3 - Review article

C2 - 27637351

AN - SCOPUS:84994834554

SN - 1040-8428

VL - 106

SP - 25

EP - 54

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

ER -

Malignant melanoma—The cradle of anti-neoplastic immunotherapy

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this